Press Releases

Press Releases
Date Title and Summary View
Jul 26, 2018 — Strong total net product sales of $3.8 billion, increased 17% Y/Y — Raising full-year total revenue guidance to ~$15 billion and REVLIMID® net sales to ~$9.7 billion — Advancing late-stage next-generation growth drivers SUMMIT, N.J.--(...
Jul 23, 2018 Final analysis showed highly statistically significant improvement in progression-free survival for R2 compared with rituximab plus placebo Global regulatory submissions planned in the first quarter of 2019 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:...
Jul 10, 2018 - First Phase III study to demonstrate a statistically significant progression-free survival improvement in first-line metastatic triple negative breast cancer (TNBC) - - IMpassion130 is the third positive Phase III study to demonstrate a clinical benefit with the investigational combination TECEN...
Jul 9, 2018 Results showed a significant reduction in transfusion burden compared to placebo Safety profile generally consistent with previously reported data Regulatory submissions planned in the United States and Europe in the first half of 2019 SUMMIT, N.J. & ...
Jul 2, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, July 26, 2018 at 9 a.m. ET to discuss second quarter 2018 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Jun 28, 2018 Results showed significant improvement in red blood cell transfusion independence compared to placebo Safety profile generally consistent with previously published data Regulatory submissions planned in the United States and Europe in the first half of 2019 ...
Jun 19, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the appointment of Jonathan Biller as Executive Vice President and General Counsel effective July 3, 2018. Mr. Biller will be responsible for global legal strategy and will serve on the company's Executive Committee. ...
Jun 3, 2018 Updated results with liso-cel underscore potential for best-in-class CAR T profile for patients with poor prognosis SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced updated six-month safety and efficacy data from the TRANSCEND (NHL-001) study of liso...
Jun 3, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced additional results from RELEVANCE, a phase III, randomized, open-label, international clinical study conducted in partnership with the Lymphoma Academic Research Organisation (LYSARC), were presented at the 54th Annual Amer...
Jun 1, 2018 High rates of response that were both deep and durable were seen at the highest dose levels. Median PFS of approximately one year achieved in heavily pre-treated patients in the active doses of the dose escalation cohort Consistent response observed for both low and high BCMA expre...
1
... NextLast
Add to Briefcase = add release to Briefcase